Precise Mapping of the CD95 Pre-Ligand Assembly Domain

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Edmond, Valérie ^a,b   Ghali, Benoist ^c,d   Penna, Aubin ^a,b   Taupin, Jean Luc ^c,d,e   Daburon, Sophie ^c,d   Moreau, Jean François ^c,d,e   Legembre, Patrick ^a,b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d CNRS Bordeaux Segalen University   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELL DEATH; CONTROLLED STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; OLIGOMERIZATION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; WILD TYPE;

ANIMALS; APOPTOSIS; CELL MEMBRANE; CELL SURVIVAL; CHROMATOGRAPHY, GEL; FAS LIGAND PROTEIN; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; IMMUNOBLOTTING; MICE; PROTEIN BINDING; PROTEIN MULTIMERIZATION;

EID: 84866725900     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046236     Document Type: Article

References (29)

1. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB, (1996) Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 335: 1643-1649.
2. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, et al. (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81: 935-946.
3. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, et al. (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268: 1347-1349.
4. Bodmer JL, Schneider P, Tschopp J, (2002) The molecular architecture of the TNF superfamily. Trends in biochemical sciences 27: 19-26.
5. Jackson CE, Fischer RE, Hsu AP, Anderson SM, Choi Y, et al. (1999) Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet 64: 1002-1014.
6. Pensati L, Costanzo A, Ianni A, Accapezzato D, Iorio R, et al. (1997) Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Gastroenterology 113: 1384-1389.
7. Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, et al. (2000) Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288: 2354-2357.
8. Vaishnaw AK, Orlinick JR, Chu JL, Krammer PH, Chao MV, et al. (1999) The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest 103: 355-363.
9. Papoff G, Hausler P, Eramo A, Pagano MG, Di Leve G, et al. (1999) Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J Biol Chem 274: 38241-38250.
10. Legembre P, Beneteau M, Daburon S, Moreau JF, Taupin JL, (2003) Cutting edge: SDS-stable Fas microaggregates: an early event of Fas activation occurring with agonistic anti-Fas antibody but not with Fas ligand. Journal of immunology 171: 5659-5662.
11. Tauzin S, Chaigne-Delalande B, Selva E, Khadra N, Daburon S, et al. (2011) The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway. PLoS biology 9: e1001090.
12. Taupin JL, Miossec V, Pitard V, Blanchard F, Daburon S, et al. (1999) Binding of leukemia inhibitory factor (LIF) to mutants of its low affinity receptor, gp190, reveals a LIF binding site outside and interactions between the two cytokine binding domains. J Biol Chem 274: 14482-14489.
13. Beneteau M, Pizon M, Chaigne-Delalande B, Daburon S, Moreau P, et al. (2008) Localization of Fas/CD95 into the Lipid Rafts on Down-Modulation of the Phosphatidylinositol 3-Kinase Signaling Pathway. Mol Cancer Res 6: 604-613.
14. Tauzin S, Debure L, Moreau JF, Legembre P (2011) CD95-mediated cell signaling in cancer: mutations and post-translational modulations. Cellular and molecular life sciences: CMLS.
15. Legembre P, Moreau P, Daburon S, Moreau JF, Taupin JL, (2002) Potentiation of Fas-mediated apoptosis by an engineered glycosylphosphatidylinositol-linked Fas. Cell Death Differ 9: 329-339.
16. Voisin MB, Bitard J, Daburon S, Moreau JF, Taupin JL, (2002) Separate functions for the two modules of the membrane-proximal cytokine binding domain of glycoprotein 190, the leukemia inhibitory factor low affinity receptor, in ligand binding and receptor activation. J Biol Chem 277: 13682-13692.
17. Legembre P, Moreau P, Daburon S, Moreau JF, Taupin JL, (2002) Potentiation of Fas-mediated apoptosis by an engineered glycosylphosphatidylinositol-linked Fas. Cell death and differentiation 9: 329-339.
18. Chaigne-Delalande B, Guidicelli G, Couzi L, Merville P, Mahfouf W, et al. (2008) The immunosuppressor mycophenolic acid kills activated lymphocytes by inducing a nonclassical actin-dependent necrotic signal. Journal of immunology 181: 7630-7638.
19. Kishimoto T (1994) Signal transduction through homo- or heterodimers of gp130. Stem Cells 12 Suppl 1: 37-44; discussion 44-35.
20. Stahl N, Boulton TG, Farruggella T, Ip NY, Davis S, et al. (1994) Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 263: 92-95.
21. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, et al. (1995) A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. The Journal of biological chemistry 270: 7795-7798.
22. Garcia-Fuster MJ, Ferrer-Alcon M, Miralles A, Garcia-Sevilla JA, (2004) Deglycosylation of Fas receptor and chronic morphine treatment up-regulate high molecular mass Fas aggregates in the rat brain. European journal of pharmacology 496: 63-69.
23. Li Y, Yang X, Nguyen AH, Brockhausen I, (2007) Requirement of N-glycosylation for the secretion of recombinant extracellular domain of human Fas in HeLa cells. The international journal of biochemistry & cell biology 39: 1625-1636.
24. Keppler OT, Peter ME, Hinderlich S, Moldenhauer G, Stehling P, et al. (1999) Differential sialylation of cell surface glycoconjugates in a human B lymphoma cell line regulates susceptibility for CD95 (APO-1/Fas)-mediated apoptosis and for infection by a lymphotropic virus. Glycobiology 9: 557-569.
25. Peter ME, Hellbardt S, Schwartz-Albiez R, Westendorp MO, Walczak H, et al. (1995) Cell surface sialylation plays a role in modulating sensitivity towards APO-1-mediated apoptotic cell death. Cell Death Differ 2: 163-171.
26. Hoogwater FJ, Nijkamp MW, Smakman N, Steller EJ, Emmink BL, et al. (2010) Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 138: 2357-2367.
27. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, et al. (2008) Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13: 235-248.
28. Letellier E, Kumar S, Sancho-Martinez I, Krauth S, Funke-Kaiser A, et al. (2010) CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 32: 240-252.
29. O'Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, et al. (2009) Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 461: 659-663.